[Cystatin C: Biomarker of cardiovascular risk in HIV].

Autor: Ghelfi AM; Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina. Electronic address: albertinaghelfi@hotmail.com., Galván MR; Servicio de Retrovirus, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina., Fay F; Cibic Laboratorios, Rosario, Sante Fe, Argentina., Herrera JN; Servicio de Clínica Médica y de Retrovirus, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina., Elias F; Cibic Laboratorios, Rosario, Sante Fe, Argentina., Brescia H; Cibic Laboratorios, Rosario, Sante Fe, Argentina., Garavelli F; Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina., Rossi JA; Laboratorio Central, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina., Galíndez JO; Servicio de Clínica Médica y de Retrovirus, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina.
Jazyk: Spanish; Castilian
Zdroj: Hipertension y riesgo vascular [Hipertens Riesgo Vasc] 2020 Apr - Jun; Vol. 37 (2), pp. 56-63. Date of Electronic Publication: 2020 Feb 28.
DOI: 10.1016/j.hipert.2020.01.003
Abstrakt: Introduction: Patients infected with the human immunodeficiency virus (HIV) have a higher cardiovascular risk (CVR). The development of cardiovascular disease (CVD) in this population involves traditional CVR factors and factors related to the infection itself, such as chronic inflammatory status, immune dysfunction, as well as the antiretroviral therapy received. Cystatin C (CC) has shown to be useful in assessing the presence of CVR factors and CVD established in the general population, the elderly population, and patients with chronic kidney disease. An analysis was performed on this association in an HIV positive population (HIV+).
Material and Methods: Analytical, observational, cross-sectional study was conducted, and included collecting information about CVR factors and CVD in HIV+, as well as measuring CC. The patients were divided into 2 groups: Group1=high CC (≥0.95mg/L) and Group2=normal CC (<0.95mg/L).
Results: A total of 95 patients were included. Group1=27 (28.4%) and Group2=68 (71.5%). A value of CC≥0.95mg/L was related to the presence of CVD (P=.01). It was also related with and an increase in waist circumference (P=.05), neck circumference (P=.04), systolic blood pressure (P=.04), diastolic blood pressure (P=.01), Framingham score (P=.03), and Framingham score adapted for HIV (P=.01). After performing multivariate analysis with incorporation of variables associated with CVD in the bivariate analysis, only CC≥0.95mg/L continued to be related to CVD.
Conclusion: CC≥0.95mg/L was independently associated with CVD. This cut-off point was also linked to higher levels of blood pressure, and higher CVR at 10 years using the Framingham Score and Framingham Score adapted for HIV population.
(Copyright © 2020 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: